Sulbactam enhances the in vitro activity of sitafloxacin against extensively‑drug resistant Acinetobacter baumannii

Xu,Nannan; Wang,Gang; Leng,Yan; Dong,Xiaomeng; Chen,Fengzhe; Xing,Quantai

doi:10.3892/etm.2018.6630

Sulbactam enhances the in vitro activity of sitafloxacin against extensively‑drug resistant Acinetobacter baumannii

Authors:
- Nannan Xu
- Gang Wang
- Yan Leng
- Xiaomeng Dong
- Fengzhe Chen
- Quantai Xing
View Affiliations

Affiliations: Department of Infectious Disease, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Center of Disease Control and Prevention of Shandong Province, Jinan, Shandong 250014, P.R. China
Published online on: August 20, 2018 https://doi.org/10.3892/etm.2018.6630
Pages: 3485-3491
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine the in vitro activities of sulbactam and sitafloxacin against extensively‑drug resistant Acinetobacter baumannii (XDR‑A. baumannii). A total of 50 strains of XDR‑A. baumannii were isolated from clinical specimens. Broth microdilution assay was applied to determine the minimum inhibitory concentration (MIC) for sulbactam and sitafloxacin. Microdilution checkerboard method was used to determine the in vitro activity of this antimicrobial combination. Accordingly, the fractional inhibitory concentration (FIC) and FIC index (FICI) were calculated. Time‑kill study was also carried out for four strains with different susceptibilities to determine the bactericidal activities of individual or combined use of sitafloxacin and sulbactam. Isolates with MICs of sitafloxacin ≤2 mg/l were considered to be susceptible to sitafloxacin. The susceptibility rate for sitafloxacin was 92% originally. When combined with sulbactam, this rate increased to 96%. Microdilution checkerboard results indicated that, when tested in combination, sulbactam/sitafloxacin exhibited marked synergistic and partial synergistic effects on 16 and 50% of the 50 strains, respectively. Time‑kill assay suggested that sulbactam enhanced the bactericidal activity of sitafloxacin and the combination induced a synergistic effect. For strains that were not susceptible to sitafloxacin, the bactericidal activities of the combination of sitafloxacin and sulbactam at a sub‑MIC concentration were impaired. However, this impairment could be overcome with the increase of the concentration to 1X MIC. The present study demonstrated that sulbactam enhanced the in vitro antimicrobial activity of sitafloxacin against XDR‑A. baumannii.

View Figures

View References

1	Lee K, Yong D, Jeong SH and Chong Y: Multidrug-resistant acinetobacter spp.: Increasingly problematic nosocomial pathogens. Yonsei Med J. 52:879–891. 2011. View Article : Google Scholar : PubMed/NCBI
2	Peleg AY, Seifert H and Paterson DL: Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev. 21:538–582. 2008. View Article : Google Scholar : PubMed/NCBI
3	Cerqueira GM and Peleg AY: Insights into Acinetobacter baumannii pathogenicity. IUBMB Life. 63:1055–1060. 2011. View Article : Google Scholar : PubMed/NCBI
4	Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 18:268–281. 2012. View Article : Google Scholar : PubMed/NCBI
5	Corbella X, Montero A, Pujol M, Domínguez MA, Ayats J, Argerich MJ, Garrigosa F, Ariza J and Gudiol F: Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol. 38:4086–4095. 2000.PubMed/NCBI
6	Viehman JA, Nguyen MH and Doi Y: Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 74:1315–1333. 2014. View Article : Google Scholar : PubMed/NCBI
7	Chen Q, Li X, Zhou H, Jiang Y, Chen Y, Hua X and Yu Y: Decreased susceptibility to tigecycline in Acinetobacter baumannii mediated by a mutation in trm encoding sam-dependent methyltransferase. J Antimicrob Chemother. 69:72–76. 2014. View Article : Google Scholar : PubMed/NCBI
8	Clinical and Laboratory Standards Institute, . Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute; Wayne, PA: 2015
9	Sader HS, Flamm RK and Jones RN: Antimicrobial activity of daptomycin tested against gram-positive pathogens collected in europe, latin america, and selected countries in the asia-pacific region (2011). Diagn Microbiol Infect Dis. 75:417–422. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ji J, Du X, Chen Y, Fu Y, Wang H and Yu Y: In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii. Int J Antimicrob Agents. 41:400–401. 2013. View Article : Google Scholar : PubMed/NCBI
11	Vidaillac C, Benichou L and Duval RE: In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumanniiPseudomonas aeruginosa, and klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 56:4856–4861. 2012. View Article : Google Scholar : PubMed/NCBI
12	Huang YS, Wang JT, Sheng WH, Chuang YC and Chang SC: Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex. J Microbiol Immunol Infect. 48:545–551. 2015. View Article : Google Scholar : PubMed/NCBI
13	Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, So TM, Yasin RM, Hsueh PR, Carlos CC, et al: High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in asia. Am J Respir Crit Care Med. 184:1409–1417. 2011. View Article : Google Scholar : PubMed/NCBI
14	Munoz-price LS and Weinstein RA: Acinetobacter infection. N Engl J Med. 358:1271–1281. 2008. View Article : Google Scholar : PubMed/NCBI
15	Djeribi R, Bouchloukh W, Jouenne T and Menaa B: Characterization of bacterial biofilms formed on urinary catheters. Am J Infect Control. 40:854–859. 2012. View Article : Google Scholar : PubMed/NCBI
16	Doi Y, Murray GL and Peleg AY: Acinetobacter baumannii: Evolution of antimicrobial resistance - treatment options. Semin Respir Crit Care Med. 36:85–98. 2015. View Article : Google Scholar : PubMed/NCBI
17	Dijkshoorn L, Nemec A and Seifert H: An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 5:939–951. 2007. View Article : Google Scholar : PubMed/NCBI
18	Potron A, Poirel L and Nordmann P: Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii Mechanisms and epidemiology. Int J Antimicrob Agents. 45:568–585. 2015. View Article : Google Scholar : PubMed/NCBI
19	Göttig S, Gruber TM, Higgins PG, Wachsmuth M, Seifert H and Kempf VA: Detection of pan drug-resistant Acinetobacter baumannii in germany. J Antimicrob Chemother. 69:2578–2579. 2014. View Article : Google Scholar : PubMed/NCBI
20	Karah N, Haldorsen B, Hermansen NO, Tveten Y, Ragnhildstveit E, Skutlaberg DH, Tofteland S, Sundsfjord A and Samuelsen Ø: Emergence of OXA-carbapenemase- and 16S rRNA methylase-producing international clones of Acinetobacter baumannii in norway. J Med Microbiol. 60:515–521. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sharma PC, Jain A and Jain S: Fluoroquinolone antibacterials: A review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm. 66:587–604. 2009.PubMed/NCBI
22	Krzyściak P, Chmielarczyk A, Pobiega M, Romaniszyn D and Wójkowska-Mach J: Acinetobacter baumannii isolated from hospital-acquired infection: Biofilm production and drug susceptibility. APMIS. 125:1017–1026. 2017. View Article : Google Scholar : PubMed/NCBI
23	Saroj SD, Clemmer KM, Bonomo RA and Rather PN: Novel mechanism for fluoroquinolone resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 56:4955–4957. 2012. View Article : Google Scholar : PubMed/NCBI
24	Grochowalska A, Kozioå-Montewka M and Sobieszczańska A: Analysis of Acinetobacter baumannii resistance patterns in patients with chronic obstructive pulmonary disease (copd) in terms of choice of effective empiric antibiotic therapy. Ann Agric Environ Med. 24:307–311. 2017. View Article : Google Scholar : PubMed/NCBI
25	Keating GM: Sitafloxacin: In bacterial infections. Drugs. 71:731–744. 2011. View Article : Google Scholar : PubMed/NCBI
26	Deguchi T, Yasuda M, Kawamura T, Nakano M, Ozeki S, Kanematsu E, Nishino Y and Kawada Y: Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant klebsiella pneumoniae and enterobacter cloacae isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 41:2544–2546. 1997.PubMed/NCBI
27	Thamlikitkul V and Tiengrim S: In vitro activity of sitafloxacin against carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 42:284–285. 2013. View Article : Google Scholar : PubMed/NCBI
28	Rafailidis PI, Ioannidou EN and Falagas ME: Ampicillin/sulbactam: Current status in severe bacterial infections. Drugs. 67:1829–1849. 2007. View Article : Google Scholar : PubMed/NCBI
29	Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE and Miller AA: Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 59:1680–1689. 2015. View Article : Google Scholar : PubMed/NCBI
30	Urban C, Go E, Mariano N and Rahal JJ: Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible acinetobacter baumannii. FEMS Microbiol Lett. 125:193–197. 1995. View Article : Google Scholar
31	Poulikakos P, Tansarli GS and Falagas ME: Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant acinetobacter infections: A systematic review. Eur J Clin Microbiol Infect Dis. 33:1675–1685. 2014. View Article : Google Scholar : PubMed/NCBI
32	Odds FC: Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 52:12003. View Article : Google Scholar : PubMed/NCBI
33	Nageeb W, Metwally L, Kamel M and Zakaria S: In vitro antimicrobial synergy studies of carbapenem-resistant Acinetobacter baumannii isolated from intensive care units of a tertiary care hospital in egypt. J Infect Public Health. 8:593–602. 2015. View Article : Google Scholar : PubMed/NCBI
34	Phee LM, Betts JW, Bharathan B and Wareham DW: Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 59:4544–4550. 2015. View Article : Google Scholar : PubMed/NCBI
35	Simsek F, Gedik H, Yildirmak MT, Iris NE, Türkmen A, Ersoy A, Ersöz M and Gücüyener A: Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy? Indian J Med Microbiol. 30:448–452. 2012. View Article : Google Scholar : PubMed/NCBI